Bill Gates Backs mRNA Capacity In India, Pitches Cutting Gene Therapy Cost
Executive Summary
Billionaire philanthropist and co-chair of the Bill and Melinda Gates Foundation signals efforts underway to support building mRNA capacity in India amid the new platform’s potential beyond COVID-19 vaccines. He also highlights the need to bring down sharply the cost of gene therapies.
You may also be interested in...
Co-Inventor Of mRNA Tech Goes After Sickle Cell Anemia
After a chance encounter at a photocopy machine brewed the recipe for Pfizer and Moderna’s success with mRNA vaccines, Dr Drew Weissman has set sights on developing a single-injection therapy for sickle cell anemia.
Afrigen Chief On mRNA Vaccine Candidate, IP Hoops, Market-Shaping Efforts
Petro Terblanche, managing director of Afrigen Biologics, talks to Scrip about a range of critical issues pertaining to the mRNA COVID-19 vaccine candidate being progressed under the wider WHO-backed technology hub initiative in South Africa and which is based on publicly-available Moderna data. Various tools and approaches are on hand to tackle the labyrinth of patents involved, though the hub, the executive underscores, will not infringe intellectual property rights.
Yes We Can: South African Scientists On Their Way With mRNA Vaccine
South African researchers make own version of mRNA COVID-19 vaccine that uses “recipes” available in the public domain but one that is eventually expected to be “second generation” and can be more applicable to use in low- and middle-income countries. The initiative, under the wider WHO-backed mRNA vaccine technology hub, doesn’t see Moderna or BioNTech intellectual property as being a barrier.